Sign Out
OLOPATADINE AND MOMETASONE (RYALTRIS) contains both olopatadine hydrochloride and mometasone furoate monohydrate; therefore, the risks associated with overdosage for the individual components described as follows apply to OLOPATADINE AND MOMETASONE (RYALTRIS).
Olopatadine Hydrochloride: Symptoms of antihistamine overdose may include drowsiness in adults and, initially, agitation and restlessness, followed by drowsiness in children. There is no known specific antidote to OLOPATADINE AND MOMETASONE (RYALTRIS). Should overdose occur, symptomatic or supportive treatment is recommended, taking into account any concomitantly ingested medications.
Mometasone Furoate: Monohydrate: Because the systemic bioavailability is <1% (using a sensitive assay with a lower quantitation limit of 0.25 pg/mL) after administration of mometasone furoate via OLOPATADINE AND MOMETASONE (RYALTRIS), overdose is unlikely to require any therapy other than observation, followed by initiation of the appropriate prescribed dosage.
